Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
US Stocks Movement | STMicroelectronics rises 2% pre-market, plans to introduce humanoid robots to advance factory automation

US Stocks Movement | STMicroelectronics rises 2% pre-market, plans to introduce humanoid robots to advance factory automation

格隆汇格隆汇2026/03/16 09:09
Show original
格隆汇 March 16|A certain exchange rose 2.04% before the market, quoted at $33.54. In terms of news, last Thursday, the exchange announced a transformation plan, aiming to retrain veteran employees and introduce robots into old chip manufacturing plants to address industry challenges and avoid factory closures. At the semiconductor conference held by the industry organization SEMI in Sopot, Poland, Thomas Morgenstern, the manufacturing director of the exchange, showcased a video of a robot delivering a silicon wafer carrier into equipment. "This is the first robot we have put into use." "In the coming years, we will deploy over a hundred humanoid robots inside the factory to undertake various operational tasks."
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

US Stock Movement | SuperX AI Technology (SUPX.US) once fell more than 2.5%, hitting an intraday low of $6.46

SuperX AI Technology's stock price declined, falling more than 2.5% at one point.

智通财经•2026/10/08 16:11

BUZZ-Pacira BioSciences participated in a Viatris acquisition deal worth 1.65 billions dollars

Latest Update October 8 – Pacira BioSciences (PCRX.O) shares surged by 44%, hitting a more than three-year high at $36.30. If the rally holds, PCRX is poised for its largest single-day gain on record. Pharmaceutical company Viatris (VTRS.O) will acquire Pacira BioSciences in a $1.65 billion cash deal, offering $36.50 per share. The offer represents a premium of approximately 44.8% over Pacira’s recent closing price of $25.20. The transaction will add Pacira’s non-opioid pain medications Exparel and Zilretta to Viatris' product portfolio. Viatris shares fell 2.6% to $17.04. JPMorgan stated: “We believe this acquisition will not significantly alter VTRS' overall financial profile in the short or long term, and expect Exparel’s sales to gradually decline post-2030 due to generic market entry.” Both parties expect to complete the transaction by the end of 2026. Including intraday fluctuations, PCRX shares have risen 40.2% year-to-date, while VTRS has gained 36.8%. (For the convenience of non-English speakers, Reuters provides automated translations of its reports into several other languages. As automated translation may contain errors or lack the necessary context, Reuters does not guarantee the accuracy of automated translated texts and provides them for readers’ convenience only. Reuters assumes no liability for any damage or losses resulting from the use of automated translation.)

路透社•2026/10/08 16:11